HEMP-001
Phase 2- Indications
- Major Depression Disorder, Atopic Dermatitis
Company intelligence / Profile preview
HEMS Clinical
Unknown/not specified, Unknown/not specified, Canadapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Hemostemix's lead product ACP‑01 has shown promising safety and efficacy in over 500 subjects across open trials and a multi-center international Phase II trial for critical limb ischemia. Early data suggest potential to form new blood vessels in ischemic tissue. NCP‑01 program aims to address neurological diseases but remains preclinical.[1][2]
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Autologous stem cell therapyBlood-derived stem cells
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on HEMS Clinical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HEMS Clinical.